Shanghai-listed FOSUN PHARMA (02196) announced that its wholly owned subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., has obtained approval from China’s National Medical Products Administration (NMPA) to initiate Phase I clinical trials of FXS0683 Tablets for hematological malignancies.

FXS0683 is an orally administered, highly potent and selective next-generation Bcl-2 inhibitor designed to induce apoptosis in malignant blood cells by inhibiting both wild-type and mutant Bcl-2 proteins. The compound is fully developed in-house by the Fosun Pharma group.

To date, the group has invested approximately RMB27.00 million in research and development of FXS0683. According to IQVIA CHPA data, China’s Bcl-2 inhibitor market generated sales of roughly RMB338.00 million in 2025, underscoring the commercial potential of novel entrants in this therapeutic class.

The investigational drug must still progress through the full clinical trial pathway and obtain further regulatory approvals before commercialization. The company cautions that drug development carries inherent uncertainties, including potential termination of trials due to safety or efficacy concerns.